Alligator Bioscience (ATORX) investor relations material

Clinical development and trial results

• Lead asset is a CD4 monoclonal antibody, metazolumab, developed for first-line metastatic pancreatic cancer and is Phase III ready.

• Combination with FOLFIRINOX chemotherapy more than tripled 24-month survival rates compared to chemotherapy alone, without significant added side effects.

• Phase II data show several patients achieving full remission or long-term tumor control, with a direct link between immune activation and clinical outcomes.

• Thirty-month readout showed 20% of patients still alive, supporting readiness for Phase III with identical endpoints and treatment schedules.

• Both FDA and European authorities have approved the Phase III protocol, and trial materials are prepared.

Expansion strategy and pipeline

• Investigator-initiated trials are underway globally, supported by grants, to build value without heavy reliance on investor funding.

• A large randomized Phase II study in France, sponsored by the government, will start in Q2 next year, validating data and expanding to other solid tumors.

• Pipeline includes preclinical drugs, such as a promising bispecific antibody (4066), and a legacy HER2 monoclonal antibody (HLX22) out-licensed for gastric cancer.

Commercial and financial outlook

• Metazolumab is expected to achieve blockbuster status, targeting 22,000–25,000 patients annually in the US and Europe.

• HLX22, if approved for gastric cancer, could generate $15–40 million in annual revenue in the early 2030s, with no direct costs or involvement.

• French government sponsorship of a $40 million Phase II study provides significant non-dilutive funding.